Manufacturing Expansion And Pulmonary Hypertension Pipeline Will Reshape Long Term Earnings Profile

Catalysts

About Liquidia

Liquidia is a biopharmaceutical company focused on therapies for pulmonary hypertension, including the PRINT enabled inhaled treprostinil product YUTREPIA and the development candidate L606.

What are the underlying business or industry changes driving this perspective?

• Rapid early adoption of YUTREPIA, with more than 900 prescriptions and over 550 patient starts in about 11 weeks, points to growing physician and patient acceptance of inhaled treprostinil delivered via PRINT technology. This can support prescription volume and product revenue as awareness broadens across the 6,500 targeted prescribers.
• Positive real world PH ILD data from the ASCENT study, including favorable tolerability, low discontinuation rates and dose escalation to higher microgram exposures, strengthens the clinical profile of YUTREPIA. This can help support longer treatment durations, which is important for revenue durability and potentially for gross margin leverage over time.
• Improving payer access, with signed contracts with all major commercial payers and an expectation that new to market blocks will be removed, is set to reduce reimbursement frictions and shift more patients from voucher and bridge programs to paid prescriptions. This directly affects reported revenue and net pricing, and in turn earnings.
• Planned expansion of North Carolina manufacturing capacity, with a new facility targeted to potentially triple production capability by 2026, positions Liquidia to meet higher volume needs for YUTREPIA and future products such as L606. This can support scaling benefits across cost of goods, operating margins and long term earnings power if demand materializes.
• Progress across the pipeline, particularly the move toward a pivotal study for L606 and upcoming R&D Day data for patients treated up to one year, builds a second potential pulmonary hypertension asset on top of YUTREPIA. This can diversify future revenue sources and create operating leverage if multiple products share the same commercial and manufacturing infrastructure.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Liquidia's revenue will grow by 118.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from -179.3% today to 41.8% in 3 years time.
• Analysts expect earnings to reach $299.9 million (and earnings per share of $3.25) by about January 2029, up from $-124.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $492.4 million in earnings, and the most bearish expecting $141.5 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.6x on those 2029 earnings, up from -22.5x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.6x.
• Analysts expect the number of shares outstanding to grow by 1.99% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• YUTREPIA’s early uptake relies heavily on voucher and bridge programs, and if payer coverage or rebate terms are less favorable over time than management anticipates, a higher than expected gross to net adjustment could limit the translation of prescription growth into product revenue and earnings.
• The company is committing capital to a new North Carolina manufacturing facility that is expected to potentially triple capacity by 2026. If long term demand for inhaled treprostinil products does not match this added capacity, underutilization could weigh on cost of goods, operating margins and overall earnings.
• Long term reliance on positive ASCENT study observations and real world experience to support positioning as a preferred prostacyclin option could be challenged if future data sets, competitor studies or label updates change physician views on relative efficacy and tolerability. This would directly affect YUTREPIA related revenue and profit margins.
• Liquidia’s growth outlook depends on broader prostacyclin use across PAH and PH ILD over many years. Any change in treatment patterns, such as increased use of alternative drug classes or competing delivery technologies, could slow new patient starts and switches, with a direct impact on prescription volumes, net revenue and earnings.
• The longer term story assumes that L606 progresses through pivotal development and eventually adds a second pulmonary hypertension revenue stream. If trial outcomes, regulatory feedback or exclusivity around competitor programs limit its path, the company could remain more dependent on a single commercial asset, which would constrain diversification of revenue and reduce potential operating leverage in earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $44.0 for Liquidia based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $67.0, and the most bearish reporting a price target of just $16.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $717.7 million, earnings will come to $299.9 million, and it would be trading on a PE ratio of 16.6x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $32.15, the analyst price target of $44.0 is 26.9% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.